Clinical Trial Update: Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of bevacizumab, irinotecan, and temozolomide in relapsed or refractory neuroblastoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED | Results posted: 2019-11-13